Exelixis (EXEL) Inventory Average (2013 - 2026)
Exelixis (EXEL) posted quarterly Inventory Average of $24.1 million for Q2 2026, up 2.22% year-over-year from $23.6 million in Q2 2025, and down 1.62% quarter-over-quarter from $24.5 million in Q1 2026.
Analysis
Exelixis (EXEL) Inventory Average (2013 - 2026) Analysis & Trends
Exelixis' Inventory Average history runs 14 years deep, the most recent figure standing at $24.1 million for Q2 2026.
- In Q2 2026, Inventory Average rose 2.22% year-over-year to $24.1 million; the TTM figure through Apr 2026 stood at $24.1 million (up 2.22% YoY), while the FY2026 annual figure was $22.0 million, up 10.99% from the prior year.
- Inventory Average for Q2 2026 stood at $24.1 million, down from $24.5 million in the prior quarter.
- The five-year high for Inventory Average was $31.6 million in Q1 2023, with the low at $19.2 million in Q1 2024.
- The 5-year median for Inventory Average is $24.5 million (2026), against an average of $25.4 million.
- The sharpest annual moves came in 2022 and 2024: Inventory Average increased 23.62% in 2022, then sank 39.2% in 2024.
- Exelixis' Inventory Average stood at $30.0 million in 2022, then decreased by 29.51% to $21.2 million in 2023, then declined by 1.59% to $20.8 million in 2024, then advanced by 22.24% to $25.4 million in 2025, then decreased by 5.1% to $24.1 million in 2026.
- Business Quant data shows EXEL's Inventory Average at $24.1 million in Q2 2026, $24.5 million in Q1 2026, and $25.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 213.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 707.10 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 90.57 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 27.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 27.67 Mn |
| Apr 3, 2026 | 24.15 Mn |
| Jan 2, 2026 | 24.54 Mn |
| Oct 3, 2025 | 25.44 Mn |
| Jul 4, 2025 | 24.17 Mn |
| Apr 4, 2025 | 23.62 Mn |
| Jan 3, 2025 | 21.70 Mn |
| Sep 27, 2024 | 20.81 Mn |
| Jun 28, 2024 | 20.86 Mn |
| Mar 29, 2024 | 19.21 Mn |
| Dec 29, 2023 | 21.15 Mn |
| Sep 29, 2023 | 26.81 Mn |
| Jun 30, 2023 | 29.27 Mn |
| Mar 31, 2023 | 31.60 Mn |
| Dec 30, 2022 | 30.01 Mn |
| Sep 30, 2022 | 29.87 Mn |
| Jul 1, 2022 | 30.74 Mn |
| Apr 1, 2022 | 27.98 Mn |
| Dec 31, 2021 | 27.87 Mn |
| Oct 1, 2021 | 26.61 Mn |